{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:34:55Z","timestamp":1793979295126,"version":"4.8.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.drugalcdep.2025.112708","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:44:28Z","timestamp":1746737068000},"page":"112708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Designer benzodiazepines: Availability, motives, and fatalities. A systematic narrative review of human studies"],"prefix":"10.1016","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8847-4387","authenticated-orcid":false,"given":"Jan","family":"van Amsterdam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112708_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13181-018-0659-3","article-title":"Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances\u2014benzodiazepines diclazepam, flubromazepam, and pyrazolam\u2014in the UK","volume":"14","author":"Abouchedid","year":"2018","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment\u2014a nation-wide register-based open cohort study","volume":"174","author":"Abrahamsson","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib3","unstructured":"ACMD, 2016. Advisory Council on the Misuse of Drugs (ACMD). Diversion and illicit supply of medicines \u3008https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/580296\/Meds_report-_final_report_15_December_LU__2_.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40545-021-00350-7","article-title":"A mixed-methods systematic review of the prevalence, reasons, associated harms and risk-reduction interventions of over-the-counter (OTC) medicines misuse, abuse and dependence in adults","volume":"14","author":"Algarni","year":"2021","journal-title":"J. Pharm. Policy Pr."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000516165","article-title":"Explaining the differences in opioid overdose deaths between Scotland and England\/Wales: Implications for European opioid policies","volume":"27","author":"van Amsterdam","year":"2021","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0269881116675508","article-title":"Benzodiazepine maintenance in opiate substitution treatment: Good or bad? a retrospective primary care case-note review","volume":"31","author":"Bakker","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib7","unstructured":"Barnsdale L., Gordon, R., Graham, L., Walker, D., Elliott, V., Graham, B., 2016. The national drug-related deaths database (Scotland) report: analysis of deaths occurring in 2014. Information services division Scotland. 2016. Edinburgh: NHS National Services Scotland \u3008https:\/\/www.isdscotland.org\/Health-Topics\/Drugsand-Alcohol-Misuse\/Publications\/2016-03-22\/2016-03-22-NDRDD-Report.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib8","article-title":"British Columbia Centre on Substance Use (BCCSU)","author":"BCCSU","year":"2021","journal-title":"Clin. Bull.: Benzodiazepines opioids"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/add.15211","article-title":"Postmortem toxicological analyses of blood samples from 107 patients receiving opioid agonist treatment: substances detected and pooled opioid and benzodiazepine concentrations","volume":"116","author":"Bech","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-074668","article-title":"Association between benzodiazepine coprescription and mortality in people on opioid replacement therapy: a population-based cohort study","volume":"14","author":"Best","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/1355621031000069882","article-title":"Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments","volume":"8","author":"Beswick","year":"2003","journal-title":"Addict. Biol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib12","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1039\/C5AY01711D","article-title":"A preliminary investigation to group disparate batches of licit and illicit diazepam tablets using differential scanning calorimetr","volume":"7","author":"Bibi","year":"2015","journal-title":"Anal. Methods"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/dta.3119","article-title":"What's in fake \u2018Xanax\u2019?: A dosage survey of designer benzodiazepines in counterfeit pharmaceutical tablets","volume":"14","author":"Blakey","year":"2022","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib14","doi-asserted-by":"crossref","first-page":"54257","DOI":"10.21037\/apm.2019.12.09","article-title":"Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events","volume":"9","author":"Boon","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib15","unstructured":"Bounds C.G., Nelson, V.L., 2024. Benzodiazepines. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470159\/\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10550880802122620","article-title":"The impact of benzodiazepine use on methadone maintenance treatment outcomes","volume":"27","author":"Brands","year":"2008","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/ph14060560","article-title":"Designer benzodiazepines: a review of toxicology and public health risks","volume":"14","author":"Brunetti","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/15563650.2018.1510502","article-title":"Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014\u20132017","volume":"57","author":"Carpenter","year":"2019","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2023.111777","article-title":"Fentanyl concentrations in ligated femoral blood in the presence and absence of NPS benzodiazepine drugs. A review of over 1250 benzo-dope\/fentanyl toxicity cases in Alberta, Canada","author":"Chatterton","year":"2023","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-11-90","article-title":"Benzodiazepine use and misuse among patients in a methadone program","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib22","first-page":"499","article-title":"Benzodiazepines and amphetamines use among methadone maintenance participants and their associations with treatment adherence","volume":"34","author":"Cheng","year":"2021","journal-title":"Biomed. Environ. Sci."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310655","article-title":"Systematic review: The relationship between gabapentinoids, etizolam, and drug related deaths in Scotland","volume":"19","author":"Ciesluk","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/02698811221104065","article-title":"Alprazolam-related deaths in Scotland, 2004\u20132020","volume":"36","author":"Corkery","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib25","series-title":"Coronor Service British Colombia (CSBC). Illicit drug toxicity. Type of drug data","author":"CSBC","year":"2023"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.111140","article-title":"Characteristics of fatal \u2018novel\u2019 benzodiazepine toxicity in Australia","volume":"331","author":"Darke","year":"2022","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib27","unstructured":"DGHSC, 2022. DGHSC (Director General Health and Social Care). Benzodiazepine use \u2014 Current trends. Evidence review; Scottish Government. \u3008https:\/\/www.gov.scot\/publications\/evidence-review-current-trends-benzodiazepine-use-scotland\/pages\/3\/\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib28","unstructured":"DHSC, 2017. Department of Health and Social Care (DHSC). Clinical guidelines on drug misuse and dependence. Update 2017. Independent Expert Working Group. \u3008https:\/\/www.gov.uk\/government\/publications\/drug-misuse-and-dependence-uk-guidelines-on-clinical-management\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib29","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/dar.13918","article-title":"Trends in toxicological findings in unintentional opioid or stimulant toxicity deaths in Qu\u00e9bec, Canada, 2012\u20132021: Has Qu\u00e9bec entered a new era of drug-related deaths?","volume":"43","author":"Do","year":"2024","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib30","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jat\/bkae075","article-title":"Deaths involving novel benzodiazepines in Victoria, Australia from 2018 to 2022","volume":"48","author":"Drummer","year":"2024","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib32","series-title":"Street tablet use in Ireland. A Trendspotter study on use, markets, and harms","author":"Duffin","year":"2020"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108466","article-title":"Factors associated with early and later dropout from methadone maintenance treatment in specialist addiction clinics: a six-year cohort study using proportional hazards frailty models for recurrent treatment episodes","volume":"219","author":"Durand","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib34","article-title":"Trends in polysubstance use among patients in methadone maintenance treatment in Ireland: Evidence from urine drug testing 2010\u20132020","volume":"167","author":"Durand","year":"2024","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bcp.15984","article-title":"Gabapentinoids in Ireland 2010 to 2020: An observational study of trends in gabapentinoid prescribing, law enforcement drug seizures and postmortem toxicology","volume":"90","author":"Durand","year":"2024","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/neurolint14030053","article-title":"Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol. Int."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/ADM.0000000000000476","article-title":"Evaluating the impact of prescribed versus nonprescribed benzodiazepine use in methadone maintenance therapy: Results from a population-based retrospective cohort study","volume":"13","author":"Eibl","year":"2019","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/0269881119901096","article-title":"Designer benzodiazepines\u2019 pharmacological effects and potencies: how to find the information","volume":"34","author":"El Balkhi","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib39","article-title":"The rise of bromazolam in postmortem cases from Travis County, Texas and surrounding areas: 2021-2023","author":"Ellefsen","year":"2024","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib40","series-title":"New benzodiazepines in Europe. A review","article-title":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","author":"EMCDDA","year":"2021"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib41","series-title":"The misuse of benzodiazepines among high-risk opioid users in Europe","article-title":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Perspectives on drugs","author":"EMCDDA","year":"2018"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib42","unstructured":"EMCDDA, 2019. European Monitoring Centre for Drugs and Drug Addiction and Europol (EMCDDA). EU drug markets report 2019. Publications Office of the European Union, Luxembourg. \u3008https:\/\/www.euda.europa.eu\/publications\/joint-publications\/eu-drug-markets-report-2019_en\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib43","series-title":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2024: Trends and developments","author":"EMCDDA","year":"2024"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib44","series-title":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA","article-title":"Early warning system on NPS","author":"EMCDDA","year":"2021"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib45","article-title":"A qualitative study of benzodiazepine\/Z-drug and opioid co-use patterns and overdose risk: insights for future policy and practice","author":"Family","year":"2024","journal-title":"MedRxiv"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib46","author":"Ford","year":"2014","journal-title":"Guid. Use Reduct. Misuse benzodiazepines Other Hypn. anxiolytics Gen. Pract."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12954-017-0134-5","article-title":"The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario","volume":"14","author":"Franklyn","year":"2017","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109402","article-title":"Oxycodone-related deaths in Sweden 2006-2018","volume":"234","author":"Fugelstad","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/20494637221095447","article-title":"Characteristics of non-fatal overdoses and associated risk factors in patients attending a specialist community-based substance misuse service","volume":"16","author":"Ghose","year":"2022","journal-title":"Br. J. Pain."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib50","unstructured":"Gomes T., Murray, R., Kolla, G., Leece, P., Bansal, S., Besharah, J., Cahill, T., Campbell, T., Fritz, A., Munro, C., Toner, L., Watford, J., 2021. On behalf of the Ontario Drug Policy Research Network Office of the Chief Coroner for Ontario and Ontario Agency for Health Protection and Promotion (Public Health Ontario). Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. O.D.P.R. Network. \u3008https:\/\/odprn.ca\/wp-content\/uploads\/2021\/05\/Changing-Circumstances-Surrounding-Opioid-Related-Deaths.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3810\/pgm.2013.07.2684","article-title":"Risks, management, and monitoring of combination opioid, benzodiazepines, and\/or alcohol use","volume":"125","author":"Gudin","year":"2013","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jat\/bkaa043","article-title":"Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases","volume":"44","author":"Heide","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib53","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/bcp.14397","article-title":"Nonmedical use of benzodiazepines and Z-drugs in the UK","volume":"87","author":"Hockenhull","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib54","series-title":"Investigating the role of benzos in drug-related mortality \u2013 a systematic review undertaken on behalf of The Scottish National Forum on Drug-Related Deaths","author":"Johnson","year":"2016"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib57","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40120-024-00628-3","article-title":"Fake Xanax: Designer emerging benzodiazepine epidemic linked to morbidity and mortality a narrative review","volume":"13","author":"Kaye","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib58","first-page":"1","article-title":"Etizolam and Irish drug poisoning deaths","author":"Keenan","year":"2024","journal-title":"Ir. J. Psychol. Med."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","article-title":"Benzodiazepines in the management of seizures and status epilepticus: A review of routes of delivery, pharmacokinetics, efficacy, and tolerability","volume":"36","author":"Kienitz","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2019.110101","article-title":"Femoral blood concentrations of flualprazolam in 33 postmortem cases","volume":"307","author":"Kriikku","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103169","article-title":"An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods","volume":"93","author":"Laing","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109427","article-title":"Variability in the unregulated opioid market in the context of extreme rates of overdose","volume":"235","author":"Larnder","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib63","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.15585\/mmwr.mm7034a2","article-title":"Trends in nonfatal and fatal overdoses involving benzodiazepines - 38 States and the District of Columbia, 2019-2020","volume":"70","author":"Liu","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib64","first-page":"1","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad124","article-title":"Global trends in the consumption of benzodiazepines and Z-drugs in 67 countries and regions from 2008 to 2018: a sales data analysis","volume":"46","author":"Ma","year":"2023","journal-title":"Sleep"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002965","article-title":"Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records","volume":"16","author":"Macleod","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib67","doi-asserted-by":"crossref","first-page":"m2995","DOI":"10.1136\/bmj.m2995","article-title":"Doctors warned over \"street benzos\" linked to hospital admissions and deaths","author":"Mahase","year":"2020","journal-title":"BMJ 370"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib68","first-page":"15","article-title":"Is it possible to treat heroin addicts with severe comorbid benzodiazepines addiction combining enhanced methadone maintenance and clonazepam maintenance treatments? Heroin Addict","volume":"16","author":"Maremmani","year":"2014","journal-title":"Relat. Clin. Probl."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jsat.2012.11.004","article-title":"Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine","volume":"44","author":"Mark","year":"2013","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib70","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/dta.3560","article-title":"Changing trends in novel benzodiazepine use within Scottish prisons: detection, quantitation, prevalence, and modes of use","volume":"16","author":"Marland","year":"2024","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib71","author":"Matheson","year":"2021","journal-title":"Scott. Drug Deaths Taskforce. Scotl. \u2019S. benzo Chall. how we Can. Meet. it."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib72","author":"Matheson","year":"2022","journal-title":"How do we Manag. risks Str. benzos"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/pharmacy12050152","article-title":"Clinical outcomes of benzodiazepine prescribing for people receiving opioid agonist treatment: A systematic review of the evidence","volume":"12","author":"Matheson","year":"2024","journal-title":"Pharmacy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102823","article-title":"Not what the doctor ordered: Motivations for nonmedical prescription drug use among people who use illegal drugs","volume":"82","author":"May","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.drugpo.2014.10.010","article-title":"Mortality related to novel psychoactive substances in Scotland, 2012: an exploratory study","volume":"26","author":"McAuley","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103512","article-title":"From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic","volume":"100","author":"McAuley","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib77","article-title":"Increased risk of non-fatal overdose associated with non-prescribed benzodiazepine use in Scotland, UK","author":"McAuley","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib78","unstructured":"McGivern M., 2018. See inside Paisley 'Breaking Bad' pill factory after 'Blue Plague' gang busted. Daily Record. \u3008https:\/\/www.dailyrecord.co.uk\/news\/scottish-news\/amazing-cop-footage-paisley-breaking-13654075\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib79","first-page":"970","article-title":"The emergence of New Psychoactive Substance (NPS) benzodiazepines. A survey of their prevalence in opioid substitution patients using LC-MS","volume":"112","author":"McNamara","year":"2019","journal-title":"Ir. Med. J."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib80","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jat\/bkad005","article-title":"Bromazolam blood concentrations in postmortem cases\u2014a British Columbia perspective","volume":"47","author":"M\u00e9rette","year":"2023","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib81","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/1556-4029.15463","article-title":"Prevalence and blood concentrations of benzodiazepines and opioids in opioid-positive death investigations in Ontario, Canada, from 2017 to 2021","volume":"69","author":"Mocanu","year":"2024","journal-title":"J. Forens. Sci."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib82","doi-asserted-by":"crossref","unstructured":"Moola S., Munn, Z., Tufanaru, C., Aromataris, E., Sears, K., Sfetcu, R., Currie, M., Qureshi, R., Mattis, P., Lisy, K., Mu, P.-F.Systematic reviews of etiology and risk. In: Aromataris E., Munn Z. (Editors). JBI Manual for Evidence Synthesis. JBI, 2020, Chapter 7. Available from \u3008https:\/\/synthesismanual.jbi.global\u3009","DOI":"10.46658\/JBIRM-17-06"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib83","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/164_2018_154","article-title":"Designer benzodiazepines: another class of new psychoactive substances","volume":"252","author":"Moosmann","year":"2018","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/pharmacy12010013","article-title":"Benzodiazepine boom: Tracking etizolam, pyrazolam, and flubromazepam from pre-UK Psychoactive Act 2016 to present using analytical and social listening techniques","volume":"12","author":"Mullin","year":"2024","journal-title":"Pharmacy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib85","doi-asserted-by":"crossref","DOI":"10.11124\/JBIES-22-00224","article-title":"Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews","author":"Munn","year":"2023","journal-title":"JBI Evid. Synth. 21:467-471"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib86","unstructured":"NDM, 2024. Nationale Drug Monitor (NDM). Slaap- en kalmeringsmiddelen [Sleeping pills and sedatives]. \u3008https:\/\/www.nationaledrugmonitor.nl\/slaapenkalmeringsmiddelen-laatste-feiten-en-trends\/\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib87","unstructured":"NDRDI, 2024. National Drug-Related Deaths Index (NDRDI). Cathy Kelleher, Fiona Riordan, and Suzi Lyons. HRB Bulletin. Drug poisoning deaths in Ireland in 2021. \u3008https:\/\/www.drugsandalcohol.ie\/41601\/22\/HRB_%20Drug_Poisoning_Deaths_Statlink.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib88","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2215-0366(19)30301-3","article-title":"The UK Government must help end Scotland's drug-related death crisis","volume":"6","author":"Nicholls","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib89","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/dar.13052","article-title":"Etizolam: a rapid review on pharmacology, non-medical use and harms","volume":"39","author":"Nielsen","year":"2020","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib90","unstructured":"NRS, 2019. National Records of Scotland (NRS). Drug-related deaths in Scotland in 2018. \u3008https:\/\/www.nrscotland.gov.uk\/files\/\/statistics\/drug-relateddeaths\/2018\/drug-related-deaths-18-pub.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib91","unstructured":"NRS, 2022. Drug-related Deaths in Scotland in 2021. \u3008https:\/\/www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/vital-events\/deaths\/drug-related-deaths-in-scotland\/2021\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib92","unstructured":"NRS, 2023. National Records of Scotland (NRS). Drug-related deaths in Scotland in 2022. \u3008https:\/\/www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/vital-events\/deaths\/drug-related-deaths-in-scotland\/2022\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib93","unstructured":"NRS, 2024. National Records of Scotland (NRS). Drug-related Deaths in Scotland in 2023. \u3008https:\/\/www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/vital-events\/deaths\/drug-related-deaths-in-scotland\/2023\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib94","unstructured":"Nugteren-van Lonkhuyzen J.J., Visser, C.C., Mulder-Spijkerboer, H.N., van Velzen, A.G., de Lange, D.W., van Riel, Aj.P.H., 2023. NVIC (National Poison Information Center). Acute vergiftigingen bij mens en dier. NVIC Jaaroverzicht 2023 [Acute poisonings in humans and animals. NVIC Annual Report 2023]. \u3008https:\/\/assets-eu-01.kc-usercontent.com\/4ecb7ebb-946a-0154-473e-737dbc98bace\/e7995e4f-cefc-42f7-8e26-4b37348986d0\/NVIC_jaaroverzicht_2023_definitief_openbaar_final.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib95","article-title":"Retention of patients in opioid substitution treatment: A systematic review","volume":"15","author":"O'Connor","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib96","unstructured":"ONS, 2024. National Office for Statistics (ONS). Deaths related to drug poisoning in England and Wales: 2023 registrations \u3008https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2023registrations\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib97","unstructured":"ONS, 2024. Office for National Statistics (ONS). Deaths related to drug poisoning by selected substances, England and Wales in 2023. \u3008https:\/\/www.ons.gov.uk\/file?uri=\u2009\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/datasets\/deathsrelatedtodrugpoisoningbyselectedsubstances\/2023registrations\/2023substances.xlsx\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib98","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/1570159X18666200110121333","article-title":"New\/Designer Benzodiazepines\u2019: an analysis of the literature and psychonauts\u2019 trip reports","volume":"18","author":"Orsolini","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib99","doi-asserted-by":"crossref","first-page":"h2698","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/add.14886","article-title":"Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine","volume":"115","author":"Park","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib101","unstructured":"Payer D.E., Young, M.M., Maloney-Hall, B., Mill, C., Leclerc, P., Buxton, J., 2020. The Canadian Community Epidemiology Network on Drug Use & the National Drug Checking Working Group. Adulterants, contaminants and co-occurring substances in drugs on the illegal market in Canada: An analysis of data from drug seizures, drug checking and urine toxicology. Canadian Centre on Substance Use and Addiction. Ottawa, Ontario. \u3008https:\/\/www.ccsa.ca\/sites\/default\/files\/2020-04\/CCSA-CCENDU-Adulterants-Contaminants-Co-occurring-Substances-in-Drugs-Canada-Report-2020-en.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10550880802324382","article-title":"One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel","volume":"27","author":"Peles","year":"2008","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib103","unstructured":"PHO, 2023. Public Health Ontario (PHO). Characteristics of substance-related toxicity deaths in Ontario. Stimulant, opioid, benzodiazepine, and alcohol-related deaths. The Ontario Drug Policy Research Network and Public Health Ontario. \u3008https:\/\/www.publichealthontario.ca\/-\/media\/Documents\/C\/2023\/characteristics-substance-related-toxicity-deaths-ontario.pdf?rev=f5054275bb584c5ca5da76674c742aaf&sc_lang=en&hash=C1125013540EC1A0A107F0068E0C978B\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib104","unstructured":"Police Scotland, 2016. Drug Trend BulleRobertson 2021tin \u2013 Issue 13 September 2016. The illicit benzodiazepine market in Scotland. \u3008https:\/\/www.nhsborders.scot.nhs.uk\/media\/456560\/Issue-13-NOT-PROTECTIVELY-MARKED-Police-Scotland-Drug-Trend-Bulletin-2-.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib105","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/add.15488","article-title":"Benzodiazepines: the time for systematic change is now","volume":"116","author":"Robertson","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib106","first-page":"S65","article-title":"Detection of novel benzodiazepines in post-mortem cases","volume":"34","author":"Rock","year":"2022","journal-title":"Toxicol. Anal. Clin."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib107","article-title":"Impact of 'street' benzodiazepines on drug-related deaths in England, Wales and Northern Ireland","author":"Rock","year":"2024","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib108","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/add.16520","article-title":"The surge of bromazolam-related fatalities replacing other novel designer benzodiazepines-related fatalities in San Francisco","volume":"119","author":"Rodda","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103933","article-title":"The increase in benzodiazepine-laced drugs and related risks in Canada: the urgent need for effective and sustainable solutions","volume":"111","author":"Russell","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12954-021-00585-2","article-title":"Diverse psychotropic substances detected in drug and drug administration equipment samples submitted to drug checking services in Toronto, Ontario, Canada, October 2019-April 2020","volume":"19","author":"Scarfone","year":"2022","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib111","series-title":"Manual of clinical psychopharmacology","author":"Schatzberg","year":"2015"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib112","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.addbeh.2007.01.010","article-title":"Retention and illicit drug use among methadone patients in Israel: a gender comparison","volume":"32","author":"Schiff","year":"2007","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-02915-5","article-title":"Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics","volume":"24","author":"Schulz","year":"2020","journal-title":"Criti Care"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib114","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","article-title":"Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes","volume":"132","author":"Schuman-Olivier","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib115","unstructured":"Scottish Government, 2022. Evidence review: Current trends in benzodiazepine use in Scotland. \u3008https:\/\/tinyurl.com\/29a6vtvo\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib116","unstructured":"Scottish Government, 2022. Benzodiazepine use - current trends: evidence review. \u3008https:\/\/www.gov.scot\/publications\/evidence-review-current-trends-benzodiazepine-use-scotland\/pages\/1\/\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib117","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.psym.2019.02.007","article-title":"Novel ways to acquire designer benzodiazepines: A case report and discussion of the changing role of the Internet","volume":"60","author":"Shapiro","year":"2019","journal-title":"Psychosomatics"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib118","unstructured":"Shapiro H., 2016. Drugwise. NPS come of age: A UK overview. \u3008http:\/\/www.drugwise.org.uk\/wp-content\/uploads\/NPSComeofAge.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038692","article-title":"Concurrent use of opioids and benzodiazepines\/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: a case cross-over study","volume":"10","author":"Sharma","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib120","series-title":"Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications","author":"Stahl","year":"2021"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib121","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0740-5472(03)00191-0","article-title":"Sleep disturbances among methadone maintained patients","volume":"26","author":"Stein","year":"2004","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2016.06.008","article-title":"Reasons for benzodiazepine use among persons seeking opioid detoxification","volume":"68","author":"Stein","year":"2016","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib123","article-title":"Trends in co-prescribed opioids and benzodiazepines, non-prescribed opioids and benzodiazepines, and schedule-I drugs in the United States, 2013 to 2019","volume":"38","author":"Taha","year":"2024","journal-title":"Prev. Med. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib124","unstructured":"UNODC, 2017. Global UNODC, SMART Update. Report No.: Volume 18. Non-medical use of benzodiazepines: a growing threat to public health? \u3008https:\/\/www.unodc.org\/documents\/scientific\/Global_SMART_Update_2017_Vol_18.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib125","unstructured":"UNODC, 2018. United Nations Office on Drugs and Crime (UNODC). World drug report 2018. \u3008https:\/\/www.unodc.org\/wdr2018\/index.html\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib126","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/jat\/bkad058","article-title":"Flualprazolam and flubromazolam: Blood concentrations and prevalence of two novel psychoactive substances in forensic case work in Ontario, Canada","volume":"47","author":"Vekic","year":"2023","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib127","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.addbeh.2013.05.008","article-title":"Treatment or \"high\": benzodiazepine use in patients on injectable heroin or oral opioids","volume":"38","author":"Vogel","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib128","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy264","article-title":"Benzodiazepine and opioid co-usage in the US population, 1999-2014: an exploratory analysis","volume":"42","author":"Vozoris","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285583","article-title":"Drug prescriptions preceding opioid-related deaths-a register study in forensic autopsy patients","volume":"18","author":"Walde","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib130","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jat\/bkab106","article-title":"Etizolam blood concentrations in 191 forensic cases in Ontario, Canada (2019\u20132020)","volume":"46","author":"Watts","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib131","unstructured":"Wedinos, 2019. Welsh Emerging Drugs & Identification of Novel Substances (WEDINOS). Annual Report 2017\u20132018. \u3008https:\/\/www.wedinos.org\/resources\/downloads\/Philtre_Annual_Report_2017-18.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib132","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose","volume":"94","author":"White","year":"1999","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib133","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/02791072.2014.901587","article-title":"Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention","volume":"46","author":"White","year":"2014","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib134","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.28557","article-title":"Association between benzodiazepine use with or without opioid use and all-cause mortality in the United States, 1999-2015","volume":"3","author":"Xu","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib136","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17512433.2023.2170349","article-title":"Designer benzodiazepines: an update","volume":"16","author":"Yu","year":"2023","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112708_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.811130","article-title":"Polysubstance use patterns among high dose benzodiazepine users: A latent class analysis and differences between male and female use","volume":"13","author":"Zamboni","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib138","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuro.2019.02.015","article-title":"An expanding world of new psychoactive substances-designer benzodiazepines","volume":"73","author":"Zawilska","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.drugalcdep.2025.112708_bib139","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.7326\/M21-4656","article-title":"Trends in concurrent opioid and benzodiazepine prescriptions in the United States 2016 to 2019","volume":"175","author":"Zhang","year":"2022","journal-title":"Ann. Intern. Med."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:01:46Z","timestamp":1774530106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":139,"alternative-id":["S0376871625001619"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112708","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designer benzodiazepines: Availability, motives, and fatalities. A systematic narrative review of human studies","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112708"}}